ReviewOncology letters2026
Clinical value of emerging peripheral blood protein biomarkers in prostate cancer (Review).
Review in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PCa) remains among the most common genitourinary tumors in elderly men, as PCa diagnosis and treatment remain major challenges. Liquid biopsy is a minimally invasive method that causes minor harm to patients with cancer. Peripheral blood protein biomarkers provide real-time PCa information and are easily accessible. The present review summarizes recent progress in identifying candidate peripheral blood protein biomarkers of PCa, including pentraxin-3, soluble E-cadherin, serum T-cell immunoglobulin, serum B- and T-lymphocyte attenuator, myeloid differentiation factor-2, pleiotrophin, spondin 2, filamin A, soluble urokinase plasminogen activator receptor, laminin subunit β-1, Golgi membrane protein 1, vitamin D-binding protein, tumor necrosis factor receptor superfamily member 9, activated leukocyte cell adhesion molecule and trophoblastic cell-surface antigen. Notably, the present review summarizes and discusses the clinical value of these proteins in PCa prediction, diagnosis, prognosis and drug resistance monitoring. These emerging peripheral blood protein biomarkers are promising for improving PCa stratification and management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.